Nabil Hanna, Ph.D., Chief Scientific Officer, joined the Company in February 1990 as Vice President, Research and Preclinical Development. In August 1993, Dr. Hanna was appointed Senior Vice President of R&PD; and in May 1998, Dr. Hanna was promoted to Chief Scientific Officer. From 1981 to 1990, Dr. Hanna served as Associate Director and then Director of the Department of Immunology at SmithKline Beecham focusing on autoimmune and chronic inflammatory diseases. From 1978 to 1981, he was a research scientist at the NCI-Frederick Cancer Research Center, where he studied the role of immune system cells in host defenses against cancer. From 1973 to 1978, Dr. Hanna was a lecturer in the Department of Immunology at the Hebrew University Medical School in Israel, where he received his Ph.D. in Immunology. Pursuant to the Company’s agreement with CNI, Dr. Hanna is a director of CNI, now known as Cytokine PharmaSciences.
